In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.
The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
During last year’s enrollment period, millions of Medicare beneficiaries reviewed their coverage options and selected new Medicare plans for the 2025 calendar year due to changes including the plans being offered, increases in premiums and more, according to an eHealth analysis.
The Centers for Disease Control and Prevention (CDC) Division of HIV Prevention tracks outbreaks, provides education and establishes guidelines for the United States and the world, according to Terri L. Wilder, MSW, HIV/Aging Policy Advocate at SAGE, an organization that serves LGBTQ+ elders.
Blujepa is the first in a new class of oral antibiotics in 30 years. It is expected to launch in the second half of 2025 in the United States.
According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ongoing clinical studies aimed at expanding its use beyond acute pain management.
In a Q&A with Josef Witt-Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares the potential benefits and risks of the alternative non-opioid pain medication, expressing that while it could help cut down on opioid use, its long-term impact is unclear.
A growing mistrust of medical providers could be traced back to doubts about scientific validity and treatment costs, according to Luke Hansen, M.D., M.H.S., chief medical officer of Arcadia, a healthcare data analytics company.
Employers and Medicare trustees could come together and change the healthcare industry, leading to healthcare reform, according to Luke Hansen, M.D., M.H.S., and chief medical officer of Arcadia, a healthcare data analytics company.
This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
It was found that Microsoft 365 was the most frequently compromised platform, responsible for 43.3% of breaches.
Luke Hansen, M.D., M.H.S., chief medical officer of Arcadia, a healthcare data analytics company, explains that the Make America Healthy Again initiative’s focus on chronic disease support will benefit value-based care and preventative care.
Moving away from accountable care organizations (ACOs) will not lead to value-based care, according to Luke Hansen, M.D., M.H.S., and chief medical officer of Arcadia, a healthcare data analytics company.
Luke Hansen, M.D., M.H.S., and chief medical officer of Arcadia, a healthcare data analytics company, said that achieving value-based care will need to be a multipronged approach with commercial purchasers and state Medicaid programs playing a prominent role.
An overview of Arcadia, a healthcare data analytics company, according to chief medical officer, Luke Hansen, M.D., M.H.S.
Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of this year.
Trust remains a sensitive subject amongst employees as the shortage of mental health resources makes it even harder for them to build that trust with employers.
Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, spoke with Managed Healthcare Executive about what these cuts could mean for the healthcare system.
Here’s what you missed this week on Managed Healthcare Executive.
Inflammatory bowel disease is a diverse disease that affects people all over the globe. This diversity in setting and treatment options makes it difficult for researchers to estimate the exact cost of care, according to Johan Burisch, M.D., Ph.D., a gastroenterologist at Hvidovre Hospital in Denmark.
At a Senate confirmation hearing for CMS administrator, Mehmet Oz, M.D., would not answer directly whether he would support budget cuts to the Medicaid program.
Lissy Hu, M.D., MBA, CEO of Ascend Learning, was one of Managed Healthcare Executive’s 2022 Emerging Leaders in Healthcare winners. The editors caught up with Hu as part of our new “Where Are They Now?” series spotlighting the career paths of past emerging leaders.
David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the potential for extended dosing intervals.
In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and costs between patients receiving CAR T-cell therapy and those treated with the non-CAR T standard of care.
A Columbia University dermatologist argues that physicians in her specialty should be on the lookout for metabolic syndrome and obesity — and treat it.
Prevalence varies by region and is impacted by social stigma, access to preventive medicine and a lack of HIV/AIDS education, according to new research published in Health Science Reports.
Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
At the 2025 American Academy of Dermatology (AAD) meeting, Steven Daveluy, M.D., associate professor and program director of dermatology at Wayne State University, discussed ongoing barriers to the early diagnosis of hidradenitis suppurativa and the latest advancements in treatment.
